109 research outputs found
The value of screening instruments in the diagnosis of poststroke dementia
Stroke is a major cause of morbidity in the industrialized world. It often results not only in
physical disability, but also in significant cognitive impairment or dementia. Between 10
and 40% of patients with a recent stroke develop dementia.1-4 Although stroke was already
recognized as an important cause of dementia more than one hundred years ago, research
on determinants of poststroke dementia and the cognitive profile of dementia after a stroke
has strongly intensified during the last decade.
The diagnosis of dementia after a stroke is complex and poses clinicians for several problems.
Poststroke dementia is a clinical entity with very heterogeneous cognitive disturbances, that
may be characterized as cortical or subcortical, or a combination of the two. Furthermore,
cognitive functioning may be hampered by the somatic symptoms that often accompany a
stroke. In clinical practice, cognitive screening instruments take an important place, either
to select patients who need further neuropsychological testing or as a diagnostic test in
patients with obvious dementia. Most existing screening instruments that are used in a
clinical setting, however, are developed to detect dementia compatible with Alzheimer’s
disease and their value in detecting dementia after stroke is less well known.
In this thesis, I describe and discuss the diagnosis of dementia after stroke, with emphasis
on the value of screening instruments in the diagnosis of poststroke dementia. I will use the
terms dementia after stroke and poststroke dementia for any type of dementia that occurs
after a stroke, irrespective of its presumed cause
Slowly progressive isolated dysarthria: Longitudinal course, speech features, and neuropsychological deficits [1]
A short screening instrument for poststroke dementia : the R-CAMCOG
BACKGROUND AND PURPOSE: The CAMCOG is a feasible cognitive screening
instrument for dementia in patients with a recent stroke. A major
disadvantage of the CAMCOG, however, is its lengthy and relatively complex
administration for screening purposes. We therefore developed the
Rotterdam CAMCOG (R-CAMCOG), based on the original version. Our aim was to
reduce the estimated administration time to 15 minutes or less and to
retain or perhaps even improve its diagnostic accuracy. METHODS: We
analyzed the item scores on the CAMCOG of 300 consecutive stroke patients,
after exclusion of patients with a severe aphasia or lowered consciousness
level, who were entered in the Rotterdam Stroke Databank. The diagnosis of
dementia was made independent of the R-CAMCOG score, on the basis of
clinical examination and neuropsychological test results. The R-CAMCOG was
constructed in 3 steps. First, items with floor and ceiling effects were
removed. Next, subscales with no additional diagnostic value were
excluded. Finally, we removed items that did not contribute to the
homogeneity of the subscales. The diagnostic accuracy of the R-CAMCOG and
the original CAMCOG was determined by means of the area under the receiver
operating characteristic (ROC) curve. RESULTS: In the 3 steps, the number
of items was reduced from 59 to 25, divided over the subscales
orientation, memory (recent, remote, and learning), perception, and
abstraction. The subscale orientation did not reach significance in a
logistic regression model but was included in the R-CAMCOG because of its
high face validity in dementia screening. Internal validation with ROC
analysis suggests that the R-CAMCOG and the CAMCOG are equally accurate in
screening for poststroke dementia (area under the curve was 0.95 for both
tests). CONCLUSIONS: The R-CAMCOG has overcome the disadvantages of the
original CAMCOG. It is a promising, short, and easy-to-administer
screening instrument for poststroke dementia. It seems to be sufficiently
accurate for this purpose, but the test has yet to be validated in a
separate, independent study
Predictors of HPV vaccination uptake: A longitudinal study among parents
To assess among parents longitudinal predictors of human papillomavirus (HPV) vaccination uptake for their daughters, random samples of parents were identified via municipal services and s
The CAMCOG: a useful screening instrument for dementia in stroke patients
BACKGROUND and PURPOSE: Most mental screening tests focus on the detection
of cognitive deficits compatible with Alzheimer's disease. Stroke patients
who develop a dementia syndrome, however, constitute a more heterogeneous
group with both cortical and subcortical disturbances. We assessed the
diagnostic accuracy of the CAMCOG (the cognitive and self-contained part
of the Cambridge Examination for Mental Disorders of the Elderly) and the
Mini-Mental State Examination (MMSE) for dementia in patients with a
recent stroke. METHODS: In patients age
The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia
Objective: Eastern European countries are contemplating to introduce the high-risk Human Papillomavirus (HPV)-test as the primary screening test for their cervical cancer screening programme, but its optimal protocol is yet unknown. The aim of this study was to compare the costs, effects and cost-effectiveness of different primary HPV-screening protocols in Eastern Europe, using Slovenia as an example and with respect of local preferences for screening. Methods: We evaluated 968 HPV-screening protocols, which varied by screening ages, triage tests (i.e. cytology, repeat HPV and/or genotyping) and strategy for women under 35 years old, using the microsimulation model MISCAN-Cervix. Results: Within the subset of strategies that would be acceptable for Slovenian women, the optimal HPV-screening protocol is to start with two cytology tests at age 25 and 28 and switch to 5-yearly HPV screening from age 30 to 65. When also other protocols were considered, the optimal screening strategy would be 5-yearly HPV screening from age 30 to 65 only, improving the cost-effectiveness with 5%. Adding genotyping in the triage algorithm consistently improved cost-effectiveness. Sensitivity analyses showed the robustness of the results for other situations in Eastern Europe. Conclusions: Despite differences in cervical cancer epidemiology between Eastern and Western European regions where HPV screening was evaluated, the optimal screening protocol was found to be very similar. Furthermore, strategies that were considered socially acceptable to the population were found to be almost as cost-effective as less acceptable strategies and can therefore be considered a viable alternative to prevent opportunistic screening
Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study
Background: Human papillomavirus (HPV) vaccination and intensifying screening expedite cervical cancer (CC) elimination, yet also deteriorate the balance between harms and benefits of screening. We aimed to find screening strategies that eliminate CC rapidly but maintain an acceptable harms-benefits ratio of screening.
Methods: Two microsimulation models (STDSIM and MISCAN) were applied to simulate HPV transmission and CC screening for the Dutch female population between 2022 and 2100. We estimated the CC elimination year and harms-benefits ratios of screening for 228 unique scenarios varying in vaccination (coverage and vaccine type) and screening (coverage and number of lifetime invitations in vaccinated cohorts). The acceptable harms-benefits ratio was defined as the number of women needed to refer (NNR) to prevent one CC death under the current programme for unvaccinated cohorts (82.17). Results: Under current vaccination conditions (bivalent vaccine, 55% coverage in girls, 27.5% coverage in boys), maintaining current screening conditions is projected to eliminate CC by 2042, but increases the present NNR with 41%. Reducing the number of lifetime screens from presently five to three and increasing screening coverage (61% to 70%) would prevent an increase in harms and only delay elimination by 1 year. Scaling vaccination coverage to 90% in boys and girls with the nonavalent vaccine is estimated to eliminate CC by 2040 under current screening conditions, but exceeds the acceptable NNR with 23%. Here, changing from five to two lifetime screens would keep the NNR acceptable without delaying CC elimination.
Conclusions: De-intensifying CC screening in vaccinated cohorts leads to little or no delay in CC elimination while it substantially reduces the harms of screening. Therefore, de-intensifying CC screening in vaccinated cohorts should be considered to ensure acceptable harms-benefits ratios on the road to CC elimination
Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review
Background: Organised cervical cancer (CC) screening programmes are delivered in many different ways across the European Union and its regions. Our aim was to systematically review the impact of these programs on CC mortality. Methods: Two independent reviewers identified all eligible studies investigating the effect of organised screening on CC mortality in Europe. Six databases including Embase, Medline and Web of Science were searched (March 2018) with predefined inclusion and exclusion criteria. Only original studies with at least five years of follow-up were considered. Validated tools were used to assess the risk of bias of the included studies. Results: Ten observational studies were included: seven cohort and three case-control studies. No randomised controlled trials were found, and there were no eligible studies from the eastern and southern part of Europe. Among the eligible studies, seven were conducted in the twentieth century; they scored lower on the risk of bias assessment. CC mortality reduction for women attending organised screening vs. non-attenders ranged from 41% to 92% in seven studies. Reductions were similar in Western (45–92%) and Northern (41–8
Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk
Background: Several studies have investigated MRI breast cancer screening in women at increased risk, but little is known about their preferences. In this study, experiences, expectations and preferences for MRI and mammography were evaluated among women undergoing screening with MRI and/or mammography in the randomized FaMRIsc trial. Methods: A 17-item questionnaire was sent to 412 women in the FaMRIsc trial. Participants were aged 30–55 years, had a ≥20% cumulative lifetime risk, but no BRCA1/2 or TP53 gene variant, and were screened outside the population-based screening program. Women received annual mammography (mammography-group), or annual MRI and biennial mammography (MRI-group). We asked whether women trust the screening outcome, what they consider as (dis)advantages, which screening they prefer and what they expect of the early detection by the screening tools. Results: 255 (62%) women completed our questionnaire. The high chance of early cancer detection was the most important advantage of MRI screening (MRI-group: 95%; mammography-group: 74%), while this was also the main advantage of mammography (MRI-group: 57%; mammography-group: 72%). Most important disadvantages of MRI were the small tunnel and the contrast fluid (for 23–36%), and of mammography were its painfulness and X-radiation (for 48–60%). Almost the whole MRI-group and half the mammography-group preferred screening with MRI (either alone or with mammography). Discussion: Most women would prefer screening with MRI. The way women think of MRI and mammography is influenced by the screening strategy they are undergoing. Our outcomes can be used for creating information brochures when MRI will be implemented for more women
Cerebral blood flow in presymptomatic MAPT and GRN mutation carriers: A longitudinal arterial spin labeling study
Objective Frontotemporal dementia (FTD) is characterized by behavioral disturbances and language problems. Familial forms can be caused by genetic defects in microtubule-associated protein tau (MAPT), progranulin (GRN), and C9orf72. In light of upcoming clinical trials with potential disease-modifying agents, the development of sensitive biomarkers to evaluate such agents in the earliest stage of FTD is crucial. In the current longitudinal study we used arterial spin labeling MRI (ASL) in presymptomatic carriers of MAPT and GRN mutations to investigate early changes in cerebral blood flow (CBF). Methods Healthy first-degree relatives of patients with a MAPT or GRN mutation underwent ASL at baseline and follow-up after two years. We investigated cross-sectional and longitudinal differences in CBF between mutation carriers (n = 34) and controls without a mutation (n = 31). Results GRN mutation carriers showed significant frontoparietal hypoperfusion compared with controls at follow-up, whereas we found no cross-sectional group differences in the total study group or the MAPT subgroup. Longitudinal analyses revealed a significantly stronger decrease in CBF in frontal, temporal, parietal, and subcortical areas in the total group of mutation carriers and the GRN subgroup, with the strongest decrease in two mutation carriers who converted to clinical FTD during follow-up. Interpretation We demonstrated longitudinal alterations in CBF in presymptomatic FTD independent of grey matter atrophy, with the strongest decrease in individuals that developed symptoms during follow-up. Therefore, ASL could have the potential to serve as a sensitive biomarker of disease progression in the presymptomatic stage of FTD in future clinical trials
- …